months) after BC diagnosis constituted 37% of BC Medicare spending, which is substantially higher due to surgery and adjuvant therapy. 2 – 6 Additionally, elderly women aged ≥65 years have higher BC incidence compared with their younger counterparts, 7
Search Results
Ami Vyas, S. Suresh Madhavan, and Usha Sambamoorthi
Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin
different benefits were seen from adjuvant therapy. 64 Patients were followed for a median of 4 years, with 41% of patients administered fluoropyrimidine-based adjuvant therapy. Patients with intermediate tumor response benefited the most from adjuvant
Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger
was sufficient to warrant consideration of adjuvant chemotherapy. Because cancer was found to be the primary cause of death in this population, adjuvant therapy is likely to improve disease outcomes. The lower rates of adjuvant therapy use among
03689712) is in progress. Clinical trials to reduce RT-related esophagitis are also planned. CLO19-040: The Role of Adjuvant Therapy in Patients With Pathological T2N0 Resected Gastric Adenocarcinoma John Khoury, MD a ; David Macari, MD a ; Daniel Ezekwudo
William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar
experienced breast surgery team that works in a coordinated, multidisciplinary fashion to guide proper patient selection for skin-sparing mastectomy, determine optimal sequencing of the reconstructive procedures in relation to adjuvant therapies, and perform a
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, and Deborah A. Freedman-Cass
. Preoperative chemoRT may result in tumor downsizing and a decrease in tumor bulk (see “Neoadjuvant and Adjuvant Therapy for Resectable Nonmetastatic Disease,” page 885); sphincter preservation may become possible in cases where initial tumor bulk prevented
Harold J. Burstein
, hopefully unbiased, fashion. Let’s apply this strategy to two important trials in early-stage breast cancer; the HERA study, which compared 0 versus 1 versus 2 years of trastuzumab as adjuvant therapy for HER2-positive breast cancers (the comparison of 1
Alyssa G. Rieber and Richard L. Theriault
. Lancet 2005 ; 365 : 60 – 62 . 16 Winer EP Hudis C Burstein HJ . American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast
Margaret Tempero
landmark studies, such as those that defined adjuvant therapy in breast and colorectal cancers, two of the biggest success stories. So my answer to the title question is “yes,” we need a publicly funded clinical trials network. The pharmaceutical industry
Robert J. Downey and Lee M. Krug
-term survival after pulmonary resection for small cell carcinoma of the lung [comment] . Thorax 1989 ; 44 : 784 – 787 . 11 Shah SS Thompson J Goldstraw P . Results of operation without adjuvant therapy in the treatment of small cell lung cancer
